Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluating the Efficacy of Cannabidiol for Reducing Cigarette Use
NCT06218056Phase 2Recruiting
- Sponsor
- University of California, Los Angeles
- Start
- Oct 2024
- Primary completion
- Dec 2026
- Modality
- Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Nantheia ATL5 in Tobacco Use Disorder (TUD) (2 arms), sponsored by University of California, Los Angeles. Primary endpoint: Effects of CBD on nicotine intake at 8 weeks. Started Oct 2024; status: recruiting.
02
Drugs
Nantheia ATL5
03
Conditions
Tobacco Use Disorder (TUD)
Beyond the preview
Go deeper on NCT06218056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06218056.